Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OSI Pharmaceuticals

Latest From OSI Pharmaceuticals

Beyond The Pandemic, An Interview With Astellas’ Percival Barretto-Ko

Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.

Business Strategies Research and Development Strategies

GI Endoscopy: Thriving on Innovation

Growth in the gastrointestinal endoscopy products market is being driven by advancements in GI diagnostics and screening technologies and growing adoption of high definition cameras and other enhanced imaging tools designed to improve diagnostic sensitivity and specificity in vivo, decrease the number of unnecessary procedures, and improve patient outcomes. Looking to the future, technological innovation will continue to impact growth in this market as emerging minimally invasive devices help redefine the diagnosis and treatment of GI disorders.

Medical Device

Recent Dealmaking (9/2003)

Summarizing the month in European dealmaking.

See All

Company Information

UsernamePublicRestriction

Register